SIGA Technologies (SIGA) Q4 2025 earnings review
Extreme Lumpiness Continues as H2 Revenue Collapses
SIGA reported a steep deceleration in Q4 with total revenue plummeting 95% YoY to $3.8M, underscoring the extreme volatility of its government contracting model. The lack of large Strategic National Stockpile (SNS) deliveries in the second half of 2025 pushed the company into an operating loss of $9.5M for the quarter. While full-year revenue fell 32% to $94.6M, the company maintained a fortress cash position of $155M. However, a major regulatory blow looms: the EMA is expected to withdraw TPOXX's mpox indication, injecting severe risk into the company's international expansion strategy.
🐂 Bull Case
SIGA ended FY25 with $155M in cash and zero debt, providing a massive buffer to absorb quarterly volatility while sustaining shareholder returns.
A $13 million Asia Pacific order in January 2026 provides immediate revenue visibility and validates the long-term strategy of building ex-U.S. sovereign stockpiles.
🐻 Bear Case
The expected withdrawal of the mpox indication in Europe severely undercuts the drug's global utility narrative and threatens future international sales.
Because semi-fixed costs remain high regardless of delivery volumes, quarters without massive government orders result in severe, multi-million dollar operating losses.
⚖️ Verdict: 🔴
Bearish. The anticipated loss of the mpox indication in Europe is a material blow to the international growth narrative, and extreme revenue volatility resulted in consecutive operating losses in H2 2025. Without a new, large-scale U.S. government contract signed immediately, 2026 is setting up to be a deeply depressed year financially.
Key Themes
EMA Mpox Indication Withdrawal
Management has consistently touted international expansion as a key growth driver, but the anticipated EMA recommendation to withdraw TPOXX's mpox indication in March 2026 directly contradicts this optimistic narrative. While the smallpox indication remains intact, losing the mpox label deals a significant blow to the drug's perceived utility and could severely hamper future ex-U.S. stockpiling orders, representing a reversing regulatory trend.
Extreme Revenue and Margin Volatility
Management framed the year as a period of 'continued advance,' yet the data tells a different story on operating leverage. Despite full-year product sales falling 34% YoY, cost of sales only declined by 5% ($29.7M vs $31.3M). This negative operating leverage led to consecutive operating losses of $10.2M in Q3 and $9.5M in Q4. Because semi-fixed manufacturing and security costs remain steady, margins collapse during quarters without large deliveries, directly contradicting the narrative of a highly scalable business model.
Dependence on Next SNS Contract
The entire business model remains overwhelmingly dependent on the U.S. Strategic National Stockpile (SNS). With the bulk of the 19C BARDA contract historical deliveries fulfilled—save for a $26M outstanding IV TPOXX order—securing a new comprehensive long-term U.S. procurement contract is critical. Any delay due to shifting political priorities or government shutdowns poses a massive structural risk.
Asia Pacific Contract Secures Baseline
Accelerating international momentum remains the primary driver outside of the U.S. In January 2026, SIGA secured a $13 million procurement order from a recurring Asia Pacific customer. This provides immediate, non-U.S. revenue visibility for the upcoming year and validates the strategy to build direct international sovereign relationships.
Advancing the TPOXX Franchise
SIGA is actively progressing its late-stage pipeline to structurally increase stockpile requirements. Backed by $13 million in BARDA funding secured in Q2 2025, the pediatric formulation is advancing. Furthermore, the Post-Exposure Prophylaxis (PEP) indication for smallpox is tracking toward a 2026 FDA submission. Success in either avenue would significantly expand the addressable market.
Macro Biodefense Tailwinds
Despite regulatory setbacks in Europe, global biodefense budgets are expanding. The $13M Asia Pacific order and previous $6M international sales in 2025 validate that macroeconomic geopolitical tensions and national security priorities are compelling foreign governments to establish independent orthopoxvirus stockpiles.
Other KPIs
Stable. The company finished the year with $155M in cash, virtually identical to its balance at the end of 2024 ($155.4M). This demonstrates disciplined working capital management, allowing SIGA to absorb the operational cash burn of H2 2025 while having paid a $0.60 per share special dividend earlier in the year.
Decelerating margin efficiency. Full-year product sales fell 34% YoY, but cost of sales only declined by 5% (from $31.3M in 2024). This structural issue occurs because SIGA must recognize semi-fixed costs—like product stability testing, storage, and security—even during quarters with negligible deliveries, severely penalizing profitability during quiet periods.
Guidance
Decelerating. SIGA does not provide traditional annual guidance, but explicitly noted a $13 million Asia Pacific order and a $26 million U.S. IV TPOXX order are scheduled for 2026 delivery. While this establishes a baseline, it is significantly below the $94.6M generated in FY25, highlighting the urgent need for a new comprehensive U.S. procurement contract to avoid a severe revenue drop.
Key Questions
Mpox Withdrawal Fallout
Given the impending withdrawal of the EMA mpox indication, how many of your historical international customers procured TPOXX specifically for mpox versus smallpox preparedness, and have you modeled the financial impact of this regulatory loss?
U.S. RFP Timeline
With only $39 million in known deliveries for 2026, the company is facing a potential revenue cliff compared to historical run rates. What is the realistic timeline for securing a new U.S. Government RFP to fill this gap?
Margin Volatility Solutions
Is there any structural mechanism to reduce the semi-fixed cost of goods sold during 'quiet' delivery quarters to prevent operating margins from turning so deeply negative, or is this volatility permanent?